BE2016C011I2 - - Google Patents

Info

Publication number
BE2016C011I2
BE2016C011I2 BE2016C011C BE2016C011C BE2016C011I2 BE 2016C011 I2 BE2016C011 I2 BE 2016C011I2 BE 2016C011 C BE2016C011 C BE 2016C011C BE 2016C011 C BE2016C011 C BE 2016C011C BE 2016C011 I2 BE2016C011 I2 BE 2016C011I2
Authority
BE
Belgium
Prior art keywords
hypertension
diabetic
renal
pharmaceutically acceptable
primary
Prior art date
Application number
BE2016C011C
Other languages
English (en)
Dutch (nl)
Original Assignee
Novartis Pharma Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22352165&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BE2016C011(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Pharma Ag filed Critical Novartis Pharma Ag
Publication of BE2016C011I2 publication Critical patent/BE2016C011I2/nl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
BE2016C011C 1998-07-10 2016-03-07 BE2016C011I2 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US11389398A 1998-07-10 1998-07-10
EP07105179A EP1870098A3 (en) 1998-07-10 1999-07-09 Combined use of valsartan and calcium channel blockers for therapeutic purposes
EP99934647A EP1096932B1 (en) 1998-07-10 1999-07-09 Antihypertensive combination of valsartan and calcium channel blocker

Publications (1)

Publication Number Publication Date
BE2016C011I2 true BE2016C011I2 (es) 2018-12-04

Family

ID=22352165

Family Applications (1)

Application Number Title Priority Date Filing Date
BE2016C011C BE2016C011I2 (es) 1998-07-10 2016-03-07

Country Status (32)

Country Link
EP (3) EP1870098A3 (es)
JP (1) JP2002520274A (es)
KR (2) KR20040078140A (es)
CN (2) CN1234357C (es)
AT (1) ATE371448T1 (es)
AU (1) AU753486B2 (es)
BE (1) BE2016C011I2 (es)
BR (1) BR9912021A (es)
CA (2) CA2336822C (es)
CY (4) CY1107779T1 (es)
CZ (2) CZ304359B6 (es)
DE (2) DE69936992T2 (es)
DK (2) DK1096932T3 (es)
ES (2) ES2289814T3 (es)
FR (1) FR16C0008I2 (es)
HK (2) HK1036758A1 (es)
HU (1) HU229383B1 (es)
ID (1) ID27664A (es)
IL (3) IL140665A0 (es)
LU (2) LU91358I2 (es)
NL (2) NL300290I2 (es)
NO (2) NO331802B1 (es)
NZ (2) NZ527598A (es)
PL (1) PL194604B1 (es)
PT (2) PT2322174E (es)
RU (3) RU2450813C2 (es)
SG (1) SG142116A1 (es)
SI (2) SI2322174T1 (es)
SK (1) SK285863B6 (es)
TR (1) TR200100062T2 (es)
WO (1) WO2000002543A2 (es)
ZA (1) ZA200100232B (es)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1870098A3 (en) 1998-07-10 2010-07-07 Novartis Ag Combined use of valsartan and calcium channel blockers for therapeutic purposes
AU3043000A (en) * 1998-12-23 2000-07-31 Novartis Ag Use of AT-1 receptor antagonist or AT-2 receptor modulator for treating diseases associated with an increase of AT-1 or AT-2 receptors
SI1197223T1 (es) * 1999-04-28 2005-08-31 Takeda Pharmaceutical
WO2001005428A1 (fr) * 1999-07-21 2001-01-25 Takeda Chemical Industries, Ltd. Methodes preventives contre la recurrence d'une insuffisance cerebrovasculaire, et agents destines a ameliorer des troubles causes par une insuffisance cerebrovasculaire et a inhiber leur evolution
SE9903028D0 (sv) * 1999-08-27 1999-08-27 Astra Ab New use
WO2001062740A1 (en) * 2000-02-25 2001-08-30 South Alabama Medical Science Foundation Mibefradil analogues and their use
WO2001062741A1 (en) * 2000-02-25 2001-08-30 South Alabama Medical Science Foundation Tetrahydronaphtalene derivatives and their use
JP2003530343A (ja) * 2000-04-12 2003-10-14 ノバルティス アクチエンゲゼルシャフト アルドステロンシンターゼインヒビター単体またはａｔ１−レセプターアンタゴニストとの組み合わせの新規医薬使用
DE10018401A1 (de) 2000-04-13 2001-10-25 Boehringer Ingelheim Pharma Verwendung von Bradycardica bei der Behandlung von mit Hypertrophie einhergehenden Myocarderkrankungen und neue Arzneimittelkombinationen
AR033390A1 (es) * 2000-08-22 2003-12-17 Novartis Ag Una composicion farmaceutica que comprende un antagonista del receptor at1 y un potenciador de la secrecion de insulina, el uso de dicha composicion para la fabricacion de un medicamento y un kit de partes
US20060089389A1 (en) 2000-08-22 2006-04-27 Malcolm Allison Combination
BR0108823A (pt) * 2000-12-29 2002-12-10 Osmotica Corp Composição farmacêutica para o tratamento da doença cerebrovascular cognitiva
ITMI20010129A1 (it) * 2001-01-25 2002-07-25 Pharmacia & Upjohn Spa Acidi grassi essenziali nella terapia di insufficienza cardiaca e scompenso cardiaco
WO2003035046A2 (en) * 2001-10-18 2003-05-01 Novartis Ag Salts formed of an at1-receptor antagonist and a cardiovascular agent
US20030180712A1 (en) 2002-03-20 2003-09-25 Biostratum Ab Inhibition of the beta3 subunit of L-type Ca2+ channels
EG24716A (en) * 2002-05-17 2010-06-07 Novartis Ag Combination of organic compounds
US20040138306A1 (en) 2002-07-25 2004-07-15 Boehringer Ingelheim Pharma Gmbh & Co. Kg Use of a specific cyclic amine derivative or the pharmaceutically acceptable salts thereof for the treatment or prevention of heart failure
DE10335027A1 (de) * 2003-07-31 2005-02-17 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verwendung von Angiotensin II Rezeptor Antagonisten
SE0300988D0 (sv) * 2003-04-03 2003-04-03 Astrazeneca Ab New use
DE602004022284D1 (de) 2003-05-15 2009-09-10 Roskamp Res Llc Verfahren zur herstellung von medikamenten zur verringerung der amyloid-abscheidung, amyloid-neurotoxizität und mikrogliosis
US20070054947A1 (en) * 2003-05-16 2007-03-08 Cohn Jay N Pharmaceutical composition comprising valsartan
US20050065094A1 (en) 2003-09-05 2005-03-24 Boehringer Ingelheim International Gmbh Use of telmisartan for the prevention and treatment of vascular headache
WO2005053687A1 (en) * 2003-11-25 2005-06-16 Novartis Ag Combination of organic compounds
WO2005070462A2 (en) * 2004-01-12 2005-08-04 Sepracor, Inc. Compositions comprising (s)-amlodipine and an angiotensin receptor blocker and methods of their use
CN100364532C (zh) * 2004-09-30 2008-01-30 江苏恒瑞医药股份有限公司 包含氨氯地平和血管紧张素ⅱ受体抑制剂的组合物
ES2374716T3 (es) 2005-04-15 2012-02-21 Research & Innovation S.P.A. Método para prevenir, retrasar o revertir la deposición anormal de amiloide.
GT200600371A (es) * 2005-08-17 2007-03-21 Formas de dosis sólidas de valsartan y amlodipina y método para hacer las mismas
GB0520405D0 (en) * 2005-10-07 2005-11-16 Imp College Innovations Ltd Biological agents and method
KR20080066776A (ko) * 2005-11-08 2008-07-16 노파르티스 아게 안지오텐신 ⅱ 수용체 봉쇄제, 칼슘 채널 봉쇄제 및 다른활성 약제의 조합물
AR057882A1 (es) 2005-11-09 2007-12-26 Novartis Ag Compuestos de accion doble de bloqueadores del receptor de angiotensina e inhibidores de endopeptidasa neutra
KR100888131B1 (ko) * 2006-10-10 2009-03-11 한올제약주식회사 시간차 투약 원리를 이용한 심혈관계 질환 치료용 복합제제
CN101883564B (zh) 2007-10-05 2013-10-16 阿尔茨海默病学会美国公司 使用(-)-尼伐地平对映体减少淀粉状蛋白沉积、淀粉状蛋白神经毒性和小神经胶质增生的方法
CN101433536A (zh) * 2007-11-12 2009-05-20 北京瑞康医药技术有限公司 含有烟酸氨氯地平和沙坦类药物的治疗组合物
JP2011507973A (ja) * 2007-12-31 2011-03-10 ルピン・リミテッド アムロジピンとバルサルタンとの医薬組成物
WO2010006103A1 (en) * 2008-07-10 2010-01-14 Ore Pharmaceuticals Inc. Method for enhancing cognition or inhibiting cognitive decline
SI2536396T1 (sl) 2010-02-16 2017-01-31 KRKA, tovarna zdravil, d.d.,Novo mesto Postopek za pripravo oralnih trdnih odmernih oblik, ki obsegajo valsartan
IT1400309B1 (it) 2010-05-10 2013-05-24 Menarini Int Operations Lu Sa Associazione di inibitori della xantina ossidasi e calcio antagonisti e loro uso.
BR112013025222B8 (pt) * 2011-04-12 2020-05-05 Boryung Pharm composição farmacêutica anti-hipertensiva e uso da mesma
BR112014003061A2 (pt) 2011-08-12 2017-02-21 Boehringer Ingelheim Vetmedica Gmbh composição farmacêutica com sabor mascarado
JPWO2013147137A1 (ja) * 2012-03-30 2015-12-14 味の素株式会社 心不全の治療剤
CZ2013783A3 (cs) 2013-10-08 2015-04-15 Zentiva, K. S Stabilní farmaceutická kompozice obsahující amlodipin a valsartan
US20180071272A1 (en) * 2014-10-23 2018-03-15 The Trustees Of The University Of Pennsylvania Novel chronotherapy based on circadian rhythms
RU2616213C2 (ru) * 2015-07-10 2017-04-13 Государственное бюджетное образовательное учреждение высшего профессионального образования "Южно-Уральский государственный медицинский университет" Министерства здравоохранения Российской Федерации (ГБОУ ВПО ЮУГМУ Минздрава России) Способ коррекции дисфункции факторов врожденного и адаптивного иммунитета при хронической почечной недостаточности в эксперименте
PL3368080T3 (pl) * 2015-10-31 2023-09-11 Io Therapeutics, Inc. Leczenie zaburzeń układu nerwowego z zastosowaniem kombinacji agonistów rxr i hormonów tarczycy
CN105287550A (zh) * 2015-11-19 2016-02-03 哈尔滨圣吉药业股份有限公司 一种缬沙坦/非洛地平复方制剂及其制备方法
CN113730581A (zh) * 2020-05-28 2021-12-03 杭州起岸生物科技有限公司 钾atp通道调节剂在制备抗糖尿病肾病药物中的应用

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4654372A (en) 1986-01-10 1987-03-31 Warner-Lambert Company Method for using verapamil for treating stroke
GB8608335D0 (en) 1986-04-04 1986-05-08 Pfizer Ltd Pharmaceutically acceptable salts
ATE134624T1 (de) * 1990-02-19 1996-03-15 Ciba Geigy Ag Acylverbindungen
NZ242724A (en) 1991-05-15 1994-09-27 Du Pont Synergistic composition comprising an angiotensin-ii receptor antagonist and a calcium channel blocker
US5492904A (en) * 1991-05-15 1996-02-20 E. I. Du Pont De Nemours And Company Composition of angiotensin-II receptor antagonists and calcium channel blockers
WO1993017682A1 (en) * 1992-03-04 1993-09-16 Abbott Laboratories Angiotensin ii receptor antagonists
PL307258A1 (en) * 1992-07-27 1995-05-15 Pfizer Peptides capable to block calcium canals with agelenopsis aperta
US5264447A (en) * 1992-09-01 1993-11-23 Merck & Co., Inc. Angiotensin II antagonist
US5721263A (en) * 1993-06-07 1998-02-24 Takeda Chemical Industries, Ltd. Pharmaceutical composition for angiotensin II-mediated diseases
CA2125251C (en) * 1993-06-07 2005-04-26 Yoshiyuki Inada A pharmaceutical composition for angiotensin ii-mediated diseases
ES2154277T3 (es) * 1993-07-15 2001-04-01 Hoffmann La Roche Combinacion farmaceutica que contiene un inhibidor del sistema renina-angiotensina y un antagonista de endotelina.
DE69534339T2 (de) * 1994-02-08 2006-05-24 Novartis Ag Behandlung von normaldruckglaukom mit valsartan
SK117996A3 (en) 1994-03-17 1997-03-05 Ciba Geigy Ag Pharmaceutical composition for treatment of diabetic nephropathy
GB9613470D0 (en) 1996-06-27 1996-08-28 Ciba Geigy Ag Small solid oral dosage form
EP1870098A3 (en) 1998-07-10 2010-07-07 Novartis Ag Combined use of valsartan and calcium channel blockers for therapeutic purposes

Also Published As

Publication number Publication date
CZ200187A3 (en) 2001-05-16
CY1107779T1 (el) 2010-07-28
EP2322174B1 (en) 2015-09-23
SI1096932T1 (sl) 2008-04-30
CN1733307A (zh) 2006-02-15
KR20010079517A (ko) 2001-08-22
KR100550167B1 (ko) 2006-02-08
DE69936992T2 (de) 2008-03-06
LU91358I2 (fr) 2007-11-06
CZ304359B6 (cs) 2014-03-26
KR20040078140A (ko) 2004-09-08
JP2002520274A (ja) 2002-07-09
HK1036758A1 (en) 2002-01-18
HK1152897A1 (en) 2012-03-16
HUP0102828A3 (en) 2002-11-28
FR16C0008I1 (es) 2016-04-15
PL194604B1 (pl) 2007-06-29
NL300290I2 (nl) 2008-11-03
RU2243768C2 (ru) 2005-01-10
CA2336822C (en) 2009-11-17
NO20010113L (no) 2001-03-09
HUP0102828A2 (hu) 2002-04-29
WO2000002543A2 (en) 2000-01-20
PT2322174E (pt) 2015-10-27
SK312001A3 (en) 2001-06-11
WO2000002543A3 (en) 2000-06-29
ATE371448T1 (de) 2007-09-15
CA2678722A1 (en) 2000-01-20
FR16C0008I2 (fr) 2018-06-08
CY2016006I2 (el) 2016-10-05
CA2678722C (en) 2013-08-27
NL300290I1 (es) 2007-11-01
EP1096932A2 (en) 2001-05-09
DE69936992D1 (de) 2007-10-11
NO20010113D0 (no) 2001-01-08
LU92992I2 (fr) 2016-05-09
CZ299429B6 (cs) 2008-07-23
NO2012013I2 (no) 2014-10-27
RU2012110522A (ru) 2013-09-27
NZ527598A (en) 2005-04-29
EP2322174A3 (en) 2011-07-27
AU5034999A (en) 2000-02-01
NO2012013I1 (no) 2012-07-30
EP1096932B1 (en) 2007-08-29
IL213926A0 (en) 2011-07-31
CY2016006I1 (el) 2016-10-05
RU2450813C2 (ru) 2012-05-20
CN1234357C (zh) 2006-01-04
EP1870098A2 (en) 2007-12-26
IL140665A (en) 2012-12-31
CY2007026I1 (el) 2009-11-04
TR200100062T2 (tr) 2001-06-21
NZ509260A (en) 2003-09-26
DE122007000055I1 (de) 2007-12-13
CA2336822A1 (en) 2000-01-20
DK1096932T3 (da) 2007-10-15
IL140665A0 (en) 2002-02-10
ID27664A (id) 2001-04-19
EP1870098A3 (en) 2010-07-07
SG142116A1 (en) 2008-05-28
SK285863B6 (sk) 2007-10-04
AU753486B2 (en) 2002-10-17
ES2289814T3 (es) 2008-02-01
DK2322174T3 (en) 2015-10-12
BR9912021A (pt) 2001-04-03
ZA200100232B (en) 2002-04-09
PT1096932E (pt) 2007-09-21
NL300800I2 (es) 2016-07-27
EP2322174A2 (en) 2011-05-18
CY2007026I2 (el) 2009-11-04
NO331802B1 (no) 2012-04-10
SI2322174T1 (sl) 2015-12-31
HU229383B1 (en) 2013-11-28
CY1116770T1 (el) 2016-10-05
PL345897A1 (en) 2002-01-14
ES2552639T3 (es) 2015-12-01
CN1312715A (zh) 2001-09-12

Similar Documents

Publication Publication Date Title
BE2016C011I2 (es)
BE2016C025I2 (es)